Table 2 Characteristics of all mCRPC patients included in this study for Lu-177-PSMA-617 therapy
PSMA-617 | P6 | P7 | P8 | P9 | P10 |
|---|---|---|---|---|---|
Age | 68 | 66 | 61 | 47 | 73 |
Activity investigated cycle [MBq] | 3718 | 3743 | 3745 | 3752 | 3700 |
Diagnosis | mCRPC | mCRPC | mCRPC | mCRPC | mCRPC |
Metastases (PET/CT) | |||||
- Extend | High | High | High | High | High |
- Type (VIS = visceral, LYM = lymph, OSS = osseous) | Mainly VIS (liver), OSS, LYM | Only OSS | Mainly OSS, LYM | Mainly OSS, LYM | Mainly OSS, LYM |
Initial TNM classification | pT3b, pN1, R0, G3, Gleason 9 | pT4, N1, R1, G3, Gleason 8 | pT3b, pN1, R1, Gleason 9 | pT3a, pN1, pR1, Gleason 9 | pT4, N1, R1, Gleason 9 |
PSA [ng/ml] | 368 | 1201 | 5436 | 408 | 101 |
Pre-therapies (1, yes/0, no) | |||||
- Surgery | 0 | 1 | 1 | 1 | 1 |
- Radiotherapy | 1 | 1 | 1 | 0 | 0 |
- Anti-hormonal therapy (including bicalutamide, enzalutamide, abiraterone acetate) | 1 | 1 | 1 | 1 | 1 |
- Radionuclide therapy (Ra-223) | 0 | 1 | 0 | 1 | 1 |
- Chemotherapy (docetaxel, cabazitaxel) | 1 | 1 | 1 | 1 | 0 |
Blood pre-therapy | |||||
- Leukocytes [G/l] | 4.90 | 7.20 | 5.60 | 6.20 | 5.00 |
- Erythrocytes [T/l] | 4.31 | 4.79 | 4.08 | 4.35 | 4.00 |
- Thrombocytes [G/l] | 307 | 195 | 291 | 314 | 191 |
- Haematocrit | 0.376 | 0.406 | 0.335 | 0.377 | 0.366 |